Full Text View
Tabular View
No Study Results Posted
Related Studies
A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
This study has been completed.
Study NCT00558298   Information provided by Janssen, LP
First Received: November 12, 2007   Last Updated: March 17, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizoaffective Disorder
Schizophrenia
Additional conditions recognized in this trial
Disease
Psychotic Disorders
More general conditions related to this trial
Mental Disorders
Pathologic Processes
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
risperidone
More general drug interventions related to this trial
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Janssen, LP


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services